

# Peter Kenemans

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11656614/peter-kenemans-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35  
papers

3,640  
citations

25  
h-index

36  
g-index

36  
ext. papers

3,977  
ext. citations

9.6  
avg, IF

3.97  
L-index

#	Paper	IF	Citations
35	Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. <i>Breast Cancer Research</i> , <b>2012</b> , 14, R13	8.3	25
34	Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial. <i>Maturitas</i> , <b>2011</b> , 70, 365-72	5	35
33	Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 135-46	21.7	236
32	The effects of tibolone in older postmenopausal women. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 697-708	59.2	308
31	Endometrial effects of tibolone in elderly, osteoporotic women. <i>Obstetrics and Gynecology</i> , <b>2008</b> , 112, 653-9	4.9	17
30	Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1383-9	2.2	23
29	Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 1412-8	7.5	30
28	Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. <i>American Journal of Obstetrics and Gynecology</i> , <b>2004</b> , 191, 718-32	6.4	96
27	The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2004</b> , 31, 1479-86	8.8	42
26	Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. <i>Familial Cancer</i> , <b>2003</b> , 2, 73-8	3	54
25	Laparoscopic detection of sentinel lymph nodes followed by lymph node dissection in patients with early stage cervical cancer. <i>Gynecologic Oncology</i> , <b>2003</b> , 90, 290-6	4.9	84
24	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. <i>Journal of Pathology</i> , <b>2001</b> , 195, 451-6	9.4	539
23	Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p.. <i>International Journal of Cancer</i> , <b>2001</b> , 92, 106-114	7.5	16
22	Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. <i>International Journal of Cancer</i> , <b>2001</b> , 93, 97-106	7.5	61
21	T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>2001</b> , 94, 114-20	2.4	21
20	Tubal ligation and risk of ovarian cancer. <i>Lancet, The</i> , <b>2001</b> , 358, 844	40	51
19	Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. <b>2001</b> , 92, 106		1

18	Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. <i>International Journal of Cancer</i> , <b>2000</b> , 86, 702-12	7.5	100
17	Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. <i>Gynecologic Oncology</i> , <b>2000</b> , 76, 45-50	4.9	162
16	Sentinel node detection in cervical cancer. <i>Obstetrics and Gynecology</i> , <b>2000</b> , 96, 135-8	4.9	92
15	Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides <b>2000</b> , 86, 702		1
14	Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides <b>2000</b> , 86, 702		3
13	Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. <i>Lancet, The</i> , <b>1999</b> , 354, 20-5	4.0	542
12	Postmenopausal Hormone Replacement Therapy and Gynecological Malignancies <b>1999</b> , 225-231		0
11	Biodistribution of <sup>111</sup> In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01. <i>Cancer Immunology, Immunotherapy</i> , <b>1998</b> , 47, 39-46	7.4	16
10	Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. <i>Clinical Chemistry</i> , <b>1998</b> , 44, 1417-1422	5.5	41
9	Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. <i>Journal of Experimental Medicine</i> , <b>1997</b> , 186, 695-704	16.6	183
8	Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. <i>Cancer Letters</i> , <b>1997</b> , 116, 93-101	9.9	31
7	Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study. <i>Cancer</i> , <b>1997</b> , 80, 2712-2720	6.4	29
6	Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study <b>1997</b> , 80, 2712		1
5	CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?. <i>Cancer</i> , <b>1996</b> , 78, 118-27	6.4	26
4	Observer agreement on interpreting colposcopic images of CIN. <i>Gynecologic Oncology</i> , <b>1995</b> , 58, 206-9	4.9	77
3	The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. <i>International Journal of Cancer</i> , <b>1995</b> , 61, 306-11	7.5	297
2	Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , <b>1993</b> , 23, 1215-9	6.1	175
1	In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. <i>European Journal of Immunology</i> , <b>1993</b> , 23, 2072-7	6.1	222

